Pharming Group has nominated Fabrice Chouraqui as the successor to CEO Sijmen de Vries. His appointment will be subject to approval at an Extraordinary General Meeting of Shareholders (EGM).
Upon his appointment, Chouraqui will join the Board of Directors, while De Vries will step down as CEO. To ensure a smooth transition, De Vries will remain as a strategic advisor until December 31, 2025.
Richard Peters, Chairman of the Board of Directors, highlighted the expertise Chouraqui brings to Pharming:
“Fabrice is a highly experienced leader in the international pharmaceutical and biotechnology sectors. He brings extensive global expertise across the entire biopharmaceutical value chain, which will support Pharming in its next phase of growth.”
Chouraqui has held senior leadership roles at Novartis and Bristol-Myers Squibb, bringing a wealth of industry knowledge to Pharming.
With this appointment, Pharming reinforces its commitment to continuity and international expansion in the biotech sector.
Researchers at Leiden University Medical Center (LUMC) have mapped the mechanism of action of a promising new antibiotic. Under a cryo-electron microscope, researchers Mia Urem...
Leiden, November 12 - The project “Omics in the Polder” from Leiden University of Applied Sciences has been nominated for the RAAK Award. This award is presented annually to the...
Leiden Bio Science Park welcomes Eli Lilly, strengthening The Netherlands' position in life sciences with a $3 billion facility. Eli Lilly and Company announced plans to build a...